Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myrcludex B plus PEG-INF-a in HBV/HDV co-infection
NCT02637999Phase 2Completed
- Sponsor
- Hepatera
- Start
- Feb 2014
- Primary completion
- Jan 2016
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of bulevirtide in hepatitis D (HDV) (3 arms), sponsored by Hepatera. Primary endpoint: Hepatitis B Surface Antigen Response at 12 weeks. Started Feb 2014; status: completed.
02
Drugs
bulevirtide
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on NCT02637999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02637999.